BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help
Search Results
Documents 1-2 out of 2 found
  Current Search:  dtic: 2, dome: 27     
HTML
56%
Genta Updates Late-Stage Progress of its Phase 3 Trial of Genasense in Advanced Melanoma
AGENDA is a Phase 3, randomized, double-blind, placebo-controlled trial that is intended to support global registration of Genasense for patients with advanced melanoma.

The study is designed to confirm certain safety and efficacy results...

Pharma Live:  Apr 29 2009 7:01PM
Matching: dtic 		Find similar documents
HTML
56%
Genta Announces Completion of Patient Enrollment into Global Phase 3 Trial of Genasense in Advanced Melanoma
Completion of this trial represents a major milestone for our Company, said Dr.

Raymond P.Warrell, Jr., Gentas Chief Executive Officer.

Over the past 10 years, Genta has made a sustained and substantial commitment toward improving health...

Pharma Live:  Apr 7 2009 1:27PM
Matching: dtic 		Find similar documents

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.